60 minutes
For a patient, the value of a therapy can mean living a normal life, even for part of the day. For a payer, value can mean improvement in health for a reasonable amount of money. For a manufacturer, it can mean broad access to the given patient population that will respond positively to a drug. And then there’s the growing role of Health Technology Assessments in seeking to create a standardized, data-driven, and evidence-based approach to measuring the value of a drug. How can we meet in the middle?


Barbara Henry - Manager of Clinical Pharmacy Services, Harvard Pilgrim Health Care
Basil T. Darras, MD - Professor of Neurology, Harvard Medical School & Assoc. Neurologist in Chief, Children's Boston
Khrystal K. Davis - Founder & President of Texas Rare Alliance & Advisory Committee Member, Texas Newborn Screening
Matt Winton - VP, Head of Rare Disease Divsion, Biogen
Tara Lavelle - Assistant Professor, Tufts Medical Center Institute for Clinical Research and Health Policy Studies